Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL228997 | 0.82 | AR (0.46) | ARPTGDR2CYP11B1CYP11B2SLC6A9 | |
| SCHEMBL227546 | 0.81 | ALDH1A1 (0.46) | AR | |
| SCHEMBL223575 | 0.80 | ALDH1A1 (0.42) | — | |
| SCHEMBL4420461 | 0.78 | SSTR4 (0.53) | ARPTGDR2CYP11B1CYP11B2SLC6A9 | |
| SCHEMBL27112675 | 0.78 | AR (0.48) | ARPTGDR2CYP11B1CYP11B2SLC6A9 | |
| SCHEMBL225575 | 0.75 | AR (0.47) | ARPTGDR2CYP11B1CYP11B2SLC6A9 | |
| SCHEMBL2771927 | 0.74 | PTGDR2 (0.63) | PTGDR2USP30 | |
| SCHEMBL9677946 | 0.73 | SLC6A9 (0.46) | ARPTGDR2CYP11B1CYP11B2SLC6A9 | |
| SCHEMBL15954492 | 0.71 | MRGPRX4 (0.34) | ARSSTR4MRGPRX4 | |
| SCHEMBL20450064 | 0.71 | AAK1 (0.49) | ARPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | AR 9/4885PTGDR2 497/4885CYP11B1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.